Lab Notes: Endo acquires 6 product candidates for $35M; NiKang signs deal worth up to $218M By: Philadelphia Business Journal via Business Journals May 06, 2022 at 12:34 PM EDT Marinus Pharmaceuticals resumes late-stage testing of its experimental seizure medication. Read More >> Related Stocks: Harbor Disruptive Innovation ETF
